Core Insights - Wolters Kluwer has repurchased 190,651 ordinary shares for €26.6 million at an average price of €139.36 during the period from July 17 to July 23, 2025 [2][3] - The company aims to repurchase shares worth up to €1 billion throughout 2025 as part of its share buyback program announced on February 26, 2025 [3] - Cumulatively, 4,076,507 shares have been repurchased in 2025, totaling €617.2 million at an average price of €151.40 [3] Share Buyback Program Details - The share buyback program allows for the execution of €350 million of buybacks through third parties, adhering to relevant laws and regulations [3] - Shares repurchased will be held as treasury shares and are intended for capital reduction through share cancellation [4] Company Overview - Wolters Kluwer reported annual revenues of €5.9 billion in 2024 and operates in over 40 countries, employing approximately 21,900 people [6] - The company provides professional information solutions, software, and services across various sectors including healthcare, tax, accounting, and legal [5]

Core Insights - Southwest Airlines reported second-quarter earnings and revenue that did not meet Wall Street expectations, indicating a challenging financial environment for the airline [1][2] - The airline announced a new $2 billion share buyback, signaling confidence in its long-term value despite current performance [1] - Southwest Airlines withdrew its 2025 guidance due to economic uncertainty in the U.S., reflecting broader industry concerns [1] Financial Performance - Earnings per share for the second quarter were reported at 43 cents adjusted, falling short of the expected 51 cents [2] - Revenue for the quarter was $7.24 billion, slightly below the anticipated $7.3 billion [2] Operational Adjustments - The airline plans to cut flights during off-peak periods, a strategy aimed at optimizing operations in response to fluctuating demand [1]

Core Points - Aalberts has repurchased 2,500 shares from July 14 to July 18, 2025, for a total of EUR 80,592.48, averaging EUR 32.24 per share [1] - The total shares repurchased under the buyback program up to July 18, 2025, amounts to 2,004,824 shares for EUR 59,799,126 [2] - The share buyback program is part of a larger initiative announced on February 27, 2025, with a total budget of EUR 75 million, set to conclude by October 24, 2025 [1][2] - The buyback is conducted within the authority granted by the Annual General Meeting on May 23, 2024, and adheres to the Market Abuse Regulation [3] Regulatory Compliance - The share buyback program complies with the technical standards set out in Regulation (EU) 596/2014 and Commission Delegated Regulation (EU) 2016/1052 [4]

Core Viewpoint - ASM International N.V. is actively conducting share repurchases as part of a €150 million buyback program initiated on April 30, 2025, with 43.6% of the program completed to date [1]. Group 1: Share Buyback Program - The company repurchased a total of 9,290 shares between July 16 and July 17, 2025, at an average price of €513.83, amounting to a total repurchased value of €4,773,457 [1]. - The individual transactions included 4,942 shares at €509.82 on July 16, 2025, and 4,348 shares at €518.38 on July 17, 2025 [1]. Group 2: Company Overview - ASM International N.V. is headquartered in Almere, the Netherlands, and specializes in designing and manufacturing equipment and process solutions for semiconductor device production [2]. - The company operates facilities across the United States, Europe, and Asia, and its common stock is traded on the Euronext Amsterdam Stock Exchange under the symbol ASM [2].

Core Viewpoint - JDE Peet's has repurchased a total of 190,991 shares as part of its ongoing share buyback program, reflecting the company's commitment to returning value to shareholders [1][2]. Share Buyback Program - The recent share repurchase occurred between July 14, 2025, and July 18, 2025, at an average price of EUR 24.08 per share, totaling EUR 4.6 million [1]. - To date, the total number of shares repurchased under the buyback program is 4,473,320 ordinary shares, amounting to EUR 88.0 million [2]. Company Overview - JDE Peet's is recognized as the world's leading pure-play coffee company, serving approximately 4,400 cups of coffee per second across more than 100 markets [3]. - In 2024, JDE Peet's reported total sales of EUR 8.8 billion and employed over 21,000 individuals globally [3].

Core Points - Columbus A/S has initiated a share buyback program with a total budget of DKK 16 million, running from 30 June 2025 to 11 March 2026 [1][2] - The company executed share buyback transactions from 14 July 2025 to 18 July 2025, purchasing a total of 46,056 shares at an average price of DKK 10.26, amounting to a transaction value of DKK 472,327.60 [2] - As of the latest report, Columbus A/S has repurchased a total of 164,056 shares, representing 0.13% of its share capital [2] Summary of Transactions - The accumulated shares before the recent transactions were 118,000 shares at an average purchase price of DKK 10.55, with a total transaction value of DKK 1,244,430.90 [2] - The breakdown of transactions during the specified period is as follows: - 14 July 2025: 56 shares at DKK 10.65, total DKK 596.40 - 15 July 2025: 10,000 shares at DKK 10.80, total DKK 108,000.00 - 16 July 2025: 10,000 shares at DKK 10.83, total DKK 108,268.00 - 17 July 2025: 11,000 shares at DKK 9.82, total DKK 107,972.70 - 18 July 2025: 15,000 shares at DKK 9.83, total DKK 147,490.50 [2] - The total accumulated shares under the buyback program now stands at 164,056 shares with an average purchase price of DKK 10.46 and a total transaction value of DKK 1,716,758.50 [2]

Core Viewpoint - Elis has disclosed the purchase of its own shares from July 14 to July 18, 2025, as part of its share buyback program authorized by the General Shareholders' Meeting on May 22, 2025 [2]. Summary by Relevant Sections Share Buyback Details - The total number of shares acquired during the buyback period is 111,716 shares, with an average purchase price of €24.4057 [2]. - The transactions were conducted on two platforms: XPAR and DXE, with the highest daily volume recorded on July 16, 2025, at 28,813 shares [2]. Purpose of Share Buybacks - The share buyback operations aim to cover maturing performance share plans and allocate free shares to employees as part of the "Elis for All 2025" international employee shareholding plan [2]. - Additionally, the shares are intended to be canceled in accordance with the resolution passed during the Combined General Meeting on May 22, 2025 [2].

Core Viewpoint - Wolters Kluwer has repurchased 196,897 ordinary shares for €27.4 million, part of a larger share buyback program aimed at repurchasing up to €1 billion in 2025 [2][3]. Share Buyback Program - The share buyback program was announced on February 26, 2025, with a total intended repurchase of €1 billion during the year [3]. - Cumulative shares repurchased to date in 2025 amount to 3,885,856, with a total consideration of €590.6 million and an average share price of €151.99 [3]. - For the period from May 8, 2025, to July 28, 2025, the company has engaged third parties to execute €350 million of buybacks [3]. Treasury Shares and Capital Reduction - Shares repurchased are held as treasury shares and will be used for capital reduction through share cancellation [4]. Company Overview - Wolters Kluwer reported annual revenues of €5.9 billion for 2024 and serves customers in over 180 countries, employing approximately 21,900 people [5]. - The company is headquartered in Alphen aan den Rijn, the Netherlands, and is listed on Euronext Amsterdam [6].

Core Viewpoint - Wolters Kluwer has repurchased 196,897 shares for €27.4 million, part of a larger share buyback program aimed at repurchasing up to €1 billion in 2025 [2][3]. Share Buyback Program - The share buyback program was announced on February 26, 2025, with a total planned repurchase of up to €1 billion during the year [3]. - As of the report date, a cumulative total of 3,885,856 shares have been repurchased, amounting to €590.6 million, with an average share price of €151.99 [3]. - For the period from May 8, 2025, to July 28, 2025, the company has engaged third parties to execute €350 million of buybacks [3]. Financial Overview - Wolters Kluwer reported annual revenues of €5.9 billion for 2024 and operates in over 180 countries with approximately 21,900 employees [6]. - The company is headquartered in Alphen aan den Rijn, Netherlands, and is listed on Euronext Amsterdam [6][7]. Shareholder Impact - Shares repurchased are held as treasury shares and will be used for capital reduction through share cancellation [4].

Core Viewpoint - Novartis reported strong Q2 2025 results with double-digit growth in net sales and core operating income, driven by successful product launches and pipeline advancements, alongside a commitment to a significant share buyback program [3][4][5]. Financial Performance - Q2 2025 net sales reached USD 14.1 billion, a 12% increase year-over-year, with constant currency growth of 11% [4][30]. - Operating income for Q2 2025 was USD 4.9 billion, reflecting a 21% increase, while net income rose to USD 4.0 billion, up 24% [4][9]. - Core operating income was USD 5.9 billion, a 20% increase, with a core operating income margin of 42.2% [10][30]. - Free cash flow for Q2 2025 was USD 6.3 billion, a 37% increase compared to the previous year [10][30]. - For H1 2025, net sales totaled USD 27.3 billion, up 12%, and core operating income increased by 21% to USD 11.5 billion [11][13]. Product Performance - Key growth drivers included Kisqali (+64% cc), Entresto (+22% cc), Kesimpta (+33% cc), Scemblix (+79% cc), Leqvio (+61% cc), and Pluvicto (+30% cc) [5][16]. - The top 20 brands generated USD 11.6 billion in Q2 2025, with a 16% increase year-over-year [17][18]. Strategic Initiatives - Novartis announced an up-to USD 10 billion share buyback program to enhance shareholder returns [3][5]. - The company raised its full-year 2025 guidance for core operating income growth to low teens, while maintaining high single-digit sales growth expectations [5][28]. Research and Development - Significant pipeline milestones included positive Phase III results for Pluvicto in hormone-sensitive prostate cancer and FDA approval for Vanrafia for IgAN [5][19][21]. - Ongoing trials and studies showed promising results for various therapies, including Kisqali and Scemblix, with plans for further regulatory submissions [22][23]. Capital Structure - As of June 30, 2025, net debt increased to USD 23.8 billion, primarily due to cash outflows for dividends and share repurchases [26]. - The company maintains a strong capital structure with a focus on balanced capital allocation [24][25].